Alicia K Morgans

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. doi request reprint Confronting Therapeutic Failure: A Conversation Guide
    Alicia K Morgans
    Vanderbilt University Medical Center, Nashville, Tennessee, USA Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 20:946-51. 2015
  2. doi request reprint Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach
    Alicia K Morgans
    Vanderbilt University Medical Center, Nashville, TN, USA Electronic address
    Eur Urol 68:891-8. 2015
  3. pmc Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy
    Alicia K Morgans
    School of Medicine, Vanderbilt University, Nashville, Tennessee Electronic address
    J Urol 193:1226-31. 2015
  4. pmc Bone-targeted agents: preventing skeletal complications in prostate cancer
    Alicia K Morgans
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Urol Clin North Am 39:533-46. 2012
  5. pmc The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research
    Matthew J Resnick
    Department of Urologic Surgery, Vanderbilt University, Nashville, TN, USA Geriatric Research Education and Clinical Center, VA Tennessee Valley Healthcare System, Nashville, TN, USA Electronic address
    Eur Urol 67:1019-25. 2015
  6. pmc Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy
    Alicia K Morgans
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 119:863-70. 2013
  7. doi request reprint Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment
    Matthew J Resnick
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee Geriatric Research Education and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee
    Cancer 120:1263-71. 2014
  8. pmc Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer
    Alicia K Morgans
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 187:889-93. 2012
  9. doi request reprint Renal cell cancer histological subtype distribution differs by race and sex
    Loren Lipworth
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    BJU Int 117:260-5. 2016

Detail Information

Publications9

  1. doi request reprint Confronting Therapeutic Failure: A Conversation Guide
    Alicia K Morgans
    Vanderbilt University Medical Center, Nashville, Tennessee, USA Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 20:946-51. 2015
    ..Confronting therapeutic failure is the hardest task for oncologists. We offer practical tips derived from a thorough review of the evidence and our clinical experience...
  2. doi request reprint Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach
    Alicia K Morgans
    Vanderbilt University Medical Center, Nashville, TN, USA Electronic address
    Eur Urol 68:891-8. 2015
    ..There are no universally monitored outcomes relevant to men with advanced prostate cancer, making it challenging to compare health outcomes between populations...
  3. pmc Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy
    Alicia K Morgans
    School of Medicine, Vanderbilt University, Nashville, Tennessee Electronic address
    J Urol 193:1226-31. 2015
    ..Using data from the population based PCOS we evaluated whether age at diagnosis and comorbidity impact the association of androgen deprivation therapy with incident diabetes and cardiovascular disease...
  4. pmc Bone-targeted agents: preventing skeletal complications in prostate cancer
    Alicia K Morgans
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Urol Clin North Am 39:533-46. 2012
    ..ADT results in bone loss and fragility fractures. This review describes the biology of bone metastases, skeletal morbidity, and recent advances in bone-targeted therapies to prevent skeletal complications of prostate cancer...
  5. pmc The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research
    Matthew J Resnick
    Department of Urologic Surgery, Vanderbilt University, Nashville, TN, USA Geriatric Research Education and Clinical Center, VA Tennessee Valley Healthcare System, Nashville, TN, USA Electronic address
    Eur Urol 67:1019-25. 2015
    ..Despite the paramount importance of patient-reported outcomes, little is known about the evolution of patient-reported urinary and sexual function over time...
  6. pmc Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy
    Alicia K Morgans
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 119:863-70. 2013
    ..Guidelines recommend bone density testing before and during ADT to characterize fracture risk. The authors of the current report assessed bone density testing among men who received ADT for ≥ 1 year...
  7. doi request reprint Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment
    Matthew J Resnick
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee Geriatric Research Education and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee
    Cancer 120:1263-71. 2014
    ..They also explored the associations between baseline function and age, comorbidity, and timing of baseline survey completion with respect to treatment...
  8. pmc Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer
    Alicia K Morgans
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 187:889-93. 2012
    ..Using data from a prospective clinical trial we compared bone mineral density and fracture between African-American and Caucasian men receiving androgen deprivation therapy...
  9. doi request reprint Renal cell cancer histological subtype distribution differs by race and sex
    Loren Lipworth
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    BJU Int 117:260-5. 2016
    ..To examine racial differences in the distribution of histological subtypes of renal cell carcinoma (RCC) and associations with established RCC risk factors by subtype...